CompletedNot Applicable

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

United States18 participantsStarted 2011-03

Plain-language summary

The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a potent, highly specific inhibitor of renal glucose transport \[SGLT2\].

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * T2DM * Drug Naive Or On Oral Therapy Exclusion Criteria: * Insulin Treatment * Major Organ Disease

What they're measuring

Change in Insulin Sensitivity

Timeframe: baseline, two weeks

Trial details

NCT IDNCT01439854

SponsorThe University of Texas Health Science Center at San Antonio

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06-30

Results submitted2019-09-16

View on ClinicalTrials.gov More Insulin Sensitivity trials